NRAS and melanoma: Stable expression of sh-ID3 in the NRAS-mutant melanoma M93–047 cell line also led to increased sensitivity to PD901 and to trametinib, another MEKi; this effect was recapitulated in pooled stably infected cell lines as well as two independent clones (Fig. 3C and D).